Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 4Phase NA 3Phase 1/2 3Phase 4 1Phase 2/3 1Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 141Lymphoid 43Other hematologic neoplasm 35Thoracic 6Genitourinary 6Gastrointestinal 6Myeloid 4CNS 4Tumor-Agnostic 3Gynecologic 3Breast 3Head & Neck 2Dermatologic 2Other solid neoplasm 1NET 1Endocrine 1

Conditions

Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Kidney Neoplasms 1Endometrial Neoplasms 1Anus Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 66Paclitaxel 54pembrolizumab 48Cyclophosphamide 33Cisplatin 28Bevacizumab 26Nivolumab 21Gemcitabine 18fludarabine 17liposomal doxorubicin 15Topotecan 15aldesleukin 13Filgrastim 12olaparib 11Interleukin-2 11Docetaxel 11Peripheral Blood Stem Cell Transplantation 10durvalumab 9Taxes 9Specimen Handling 9Oxaliplatin 8fludarabine phosphate 7epacadostat 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Injections 7rucaparib 6niraparib 6lenvatinib 6cemiplimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Dexamethasone × Gynecologic × Clear all
NCT04432597 2026-05-18

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
39 enrolled
GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Eisai Inc.

Phase 1/2 Recruiting
182 enrolled
BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT00531284 2017-08-15

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma

Amgen

Phase 1/2 Completed
184 enrolled 36 charts
GenitourinaryGynecologicLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Lymphoma, Multiple Myeloma, Ovarian Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡